-
Product Insights
NewNet Present Value Model: Aligos Therapeutics Inc’s ALG-009
Empower your strategies with our Net Present Value Model: Aligos Therapeutics Inc's ALG-009 report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Company Insights
Innovation and Patenting activity of Aligos Therapeutics Inc Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Aligos Therapeutics Inc Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be...
-
Product Insights
Severe Acute Respiratory Syndrome (SARS) – Drugs In Development, 2023
Global Markets Direct’s, ‘Severe Acute Respiratory Syndrome (SARS) - Drugs In Development, 2023’, provides an overview of the Severe Acute Respiratory Syndrome (SARS) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Severe Acute Respiratory Syndrome (SARS), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest...
-
Product Insights
Middle East Respiratory Syndrome (MERS) – Drugs In Development, 2023
Global Markets Direct’s, ‘Middle East Respiratory Syndrome (MERS) - Drugs In Development, 2023’, provides an overview of the Middle East Respiratory Syndrome (MERS) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Middle East Respiratory Syndrome (MERS), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ALG-009 in Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ALG-009 in Metabolic Dysfunction-Associated Steatohepatitis (MASH) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ALG-009 in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Drug Details: ALG-055009 is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ALG-009 in Non-Alcoholic Steatohepatitis (NASH)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ALG-009 in Non-Alcoholic Steatohepatitis (NASH) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ALG-009 in Non-Alcoholic Steatohepatitis (NASH) Drug Details: ALG-055009 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Jnk Inhibitors in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Jnk Inhibitors in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Jnk Inhibitors in Solid Tumor Drug Details: The drug candidate...
-
Company Profile
Aligos Therapeutics Inc – Company Profile
Aligos Therapeutics, Inc (Aligos) is a clinical-stage biopharmaceutical company that develops products for the treatment of viral infections and liver diseases. The company product pipeline includes ALG-125755 and ALG-000184 for the treatment of chronic hepatitis B (CHB) and ALG-097558 for covid 19. Aligos also provide ALG-055009 for Nonalcoholic Steatohepatitis (NASH). Its partners include Merck, Luxna Biotech, KU Leuven, AM Chemicals and Emory University. It operates in the US, Belgium, China and Australia. Aligos is headquartered in South San Francisco, California,...
Add to Basket -
Product Insights
Middle East Respiratory Syndrome (MERS) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Middle East Respiratory Syndrome (MERS) Pipeline Drugs Market Report Overview Middle East respiratory syndrome (MERS) is a viral respiratory disease caused by a coronavirus (MERS-CoV). Symptoms include fever, cough, and shortness of breath. Other symptoms include nausea, vomiting and diarrhea. The MERS pipeline drugs market research report provides comprehensive information on the MERS targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also reviews key players...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – ALG-125755
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry ALG-125755 Drug Details ALG-125755 is under development for the treatment of chronic hepatitis B....